Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Kalorama Information | PRODUCT CODE: 1148669

Cover Image

PUBLISHER: Kalorama Information | PRODUCT CODE: 1148669

Precision Cancer Therapeutics, 2022

PUBLISHED:
PAGES: 154 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Online Access (Single User License)
USD 5000
Online Access & PDF Download (10 Users)
USD 7500
Online Access & PDF Download (Unlimited Users)
USD 10000

Add to Cart

Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

The demand for more effective and tolerable cancer treatments has led to the development of novel therapeutic agents that specifically target the malignant cells. Today, advanced precision cancer therapies are available, and more are being developed each year. Although there are some older precision therapies on the market, the industry is now expanding the use of these treatments to better treat cancer victims. Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

This report “Precision Cancer Therapeutics, 2022 ” specifically focuses on five leading segments of precision therapies:

  • Monoclonal antibodies
  • Kinase inhibitors
  • Angiogenesis inhibitors
  • Proteasome inhibitors
  • CAR-T therapies
  • Other precision therapies

Additionally, smaller areas of precision therapies are covered including mTOR inhibitors, PI3K inhibitors, PARP inhibitors, apoptosis inhibitors, histone deacetylase inhibitors, CDK inhibitors, hedgehog signaling pathway inhibitors and several others.

Scope and Methodology

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress.

This report covers precision cancer therapies that do at least one of the following:

  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells

The report includes statistical information for cancers by type on a global level. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers. The report also includes a list of Phase 3 precision therapies in development. Throughout the report, several market indicators, trends and barriers are discussed.

The following are companies of focus in the report:

  • AbbVie
  • Astellas Pharma U.S., Inc
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi/Genzyme
  • Seagen Inc.
  • Takeda
Product Code: 22-719c

Table of Contents

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview and Analysis
    • Figure 1-1: Global Precision Cancer Therapeutic Market Size and Forecast, 2017-2027 ($millions)

Chapter 2: Introduction

  • Global Cancer Burden
    • Figure 2-1: Incidence of Cancer by Type, 2020
    • Figure 2-2: Distribution of Cancer Incidence by Type, 2020
  • Introduction to Cancer
  • Biochemistry of Cancer Cells
  • Causes of Cancer Growth May Shed Light on Treatment
  • Environmental Factors, DNA, RNA
    • Table 2-1: Virus Association with Human Cancer
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • Cancer Treatment Approaches
    • Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, Precision therapy)
  • What is Precision Cancer Therapy?
  • Trends in Research and Development of Precision Cancer Therapeutics
  • Monoclonal Antibodies: The Leading Area of Cancer Precision Therapy

Chapter 3: Precision Cancer Therapies: Monoclonal Antibodies

  • Monoclonal Antibody Overview
  • Market Outlook
    • Figure 3-1: Cancer Monoclonal Antibody Market, 2017-2027 ($ millions)
  • Principal Products
    • Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
    • Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
  • Avastin (bevacizumab)
  • Blincyto (blinatuomab)
  • Darzalex (daratumumab)
  • Erbitux (cetuximab)
  • Herceptin (trastuzumab)
  • Kadcyla (ado-trastuzumab emtansine)
  • Keytruda (pembrolizumab)
  • Libtayo (cemiplimab-rwlc)
  • Opdivo (nivolumab)
  • Padcev (enfortumab vedotin-jfv)
  • Perjeta (pertuzumab)
  • Rituxan (rituximab)
  • Sarclisa (isatuximab)
  • Tivdak (tisolumab vedotin-tftv)
  • Tecentriq (atezolizumab)
  • Vectibix (panitumumab)
  • Xgeva (denosumab)
  • Yervoy (ipilimumab)
    • Table 3-2: Selected Monoclonal Antibodies in Cancer Therapy
  • Late-Stage Monoclonal Antibodies Development
    • Table 3-3: Selected Late-Stage Monoclonal Antibodies in Phase 3 Development
  • Market Breakdown of Monoclonal Antibodies
  • Cancer Monoclonal Antibody Market by Target
    • Table 3-4: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
    • Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
    • Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2022 (%)
    • Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2027 (%)
  • Cancer Monoclonal Antibody Market by Type
    • Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2027 ($ millions)
    • Table 3-5: Cancer Treatment mAb Market by Type, 2022-2027 ($ millions)
    • Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2022 and 2027 ($ millions)
    • Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2022 (%)
    • Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2027 (%)
  • Regional Market Summary
    • Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2022 and 2027 ($ millions)
  • Competitor Summary
  • Merck & Co.
  • Genentech/Roche
  • Bristol-Myers Squibb
  • Janssen Biotech/J&J
  • Amgen
  • AstraZeneca
  • EMD Serono
    • Table 3-6: Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2022 ($ millions)

Chapter 4: Precision Cancer Therapies: Kinase Inhibitors

  • Kinase Inhibitor Overview
  • Market Outlook
    • Figure 4-1: Kinase Inhibitor Market, 2022-2027: CAGR 8.8% ($ millions)
  • Principal Products
    • Table 4-1: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
    • Figure 4-2: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
  • Alecensa (alectinib)
  • Alunbrig (brigatinib)
  • Imbruvica (ibrutinib)
  • Inlyta (axitinib)
  • Sprycel (dasatinib)
  • Tasigna (nilotinib)
  • Tagrisso (osimertinib)
  • Gleevec (imatinib)
  • Mekinist+Tafinlar (trametinib + dabrafenib)
  • Sutent (sunitinib)
  • Jakafi/Jakavi (ruxolitinib)
  • Nexavar (sorafenib)
  • Tukysa (tucatinib)
  • Votrient (pazopanib)
    • Table 4-2: Kinase Inhibitors in Cancer Therapy
  • Late-Stage Kinase Inhibitors Development
    • Table 4-3: Selected Phase 3 Kinase Inhibitors in Development
  • Market Breakdown of Kinase Inhibitors
  • Cancer Kinase Inhibitor Market by Target
    • Table 4-4: Cancer Kinase Inhibitor Market by Target, 2022 and Forecast 2027 ($ millions)
    • Figure 4-3: Cancer Kinase Inhibitor Market by Target, 2022 and 2027 ($ millions)
    • Figure 4-4: Kinase Inhibitor Market Distribution by Target, 2022 (%)
    • Figure 4-5: Kinase Inhibitor Market Distribution by Target, 2027 (%)
  • Cancer Kinase Inhibitor Market by Type
    • Figure 4-6: Development of the Kinase Inhibitor Cancer Treatment Market, 2010-2027 ($ millions)
    • Table 4-5: Cancer Treatment Kinase Inhibitor Market by Type, 2022-2027 ($ millions)
    • Figure 4-7: Kinase Inhibitor Market by Cancer Indication, 2022 and 2027 ($ millions)
    • Figure 4-8: Kinase Inhibitor Market Distribution by Cancer Indication, 2022 (%)
    • Figure 4-9: Kinase Inhibitor Market Distribution by Cancer Indication, 2027 (%)
  • Regional Market Summary
    • Figure: 4-10: Cancer Kinase Inhibitor Market Summary by Geographic Region, 2022 and 2027 ($ millions)
  • Competitor Summary
  • Novartis
  • AstraZeneca
  • AbbVie
  • Johnson & Johnson
  • Pfizer
  • Bristol-Myers Squibb
  • Roche/Genentech
    • Table 4-6: Cancer Kinase Inhibitor Competitor Market Share, 2022 ($ millions)

Chapter 5: Precision Cancer Therapies: Angiogenesis Inhibitors

  • Angiogenesis Inhibitor Overview
  • Market Outlook
    • Figure 5-1: Angiogenesis Inhibitor Market, 2017-2027 ($ millions)
  • Principal Products
  • Pomalyst/Imnovid (pomalidomide)
  • Revlimid (lenalidomide)
  • Thalomid (thalidomide)
  • Zaltrap (ziv-aflibercept)
    • Table 5-1: Angiogenesis Inhibitors in Cancer Therapy
  • Late-Stage Angiogenesis Inhibitor Phase 3 Development
    • Table 5-2: Selected Phase 3 Angiogenesis Inhibitor Development
  • Regional Market Summary
    • Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
  • Competitor Summary

Chapter 6: Precision Cancer Therapies: CAR-T Therapies

  • CAR-T Overview
  • Manufacturing Process for CAR-T
  • Leukapheresis
  • Activation
  • Transduction
  • Expansion
  • Regulatory Developments
  • Market Outlook
    • Figure 6-1: CAR-T Market, 2017-2027 ($ millions)
  • Principal Products
  • Abecma
  • Breyanzi
  • Carvykti
  • Kymriah
  • Tecartus
  • Yescarta
  • Late-Stage CAR-T Therapies Development
    • Table 6-1: Phase III Development ¾ CAR-T Therapies, Select Projects
  • Regional Market Summary
    • Figure: 6-2: Cancer CAR-T Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
  • Competitor Summary

Chapter 7: Precision Cancer Therapies: Proteasome Inhibitors

  • Proteasome Inhibitor Overview
  • Market Outlook
    • Figure 7-1: Proteasome Inhibitor Market, 2022-2027 ($ millions)
  • Principal Products
  • Kyprolis (carfilzomib)
  • Ninlaro (ixazomib)
  • Velcade (bortezomib)
    • Table 7-1: Proteasome Inhibitors in Cancer Therapy
  • Regional Market Summary
    • Figure 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
  • Competitor Summary
  • Takeda
  • Amgen
    • Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2022 ($ millions)

Chapter 8: Precision Cancer Therapies: Other Precision Therapies

  • Other Precision Therapies Overview
  • Market Outlook
    • Figure 8-1: Other Precision Therapies Market, 2017-2027 ($ millions)
  • Principal Products
  • mTOR Inhibitor 34XXXXX Afinitor (everolimus)
  • mTOR Inhibitor 34XXXXX Torisel (temsirolimus)
  • PI3K Inhibitor 34XXXXX Zydelig
  • PARP Inhibitor 34XXXXX Lynparza
  • PARP Inhibitor 34XXXXX Zejula
  • Apoptosis Inducer 34XXXXX Venclexta
  • CDK Inhibitors - Ibrance (palbociclib)
  • CDK Inhibitors - Kisqali (ribociclib)
    • Table 8-1: Other Precision Cancer Therapies
  • Late-Stage Other Therapies Development
    • Table 8-2: Select Phase 3 Other Therapies Development
  • Regional Market Summary
    • Figure: 8-2: Other Precision Therapies Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)

Chapter 9: Market Summary

  • Market Influences
  • Global Demographics
    • Table 9-1: Global Population, through 2050 (population in millions)
  • Aging Population
    • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • Cancer: A Growing Economic Burden
  • Cost Containment
    • Table 9-2: The Cost of Monoclonal Antibodies (2020-2021)
  • Reimbursement Landscape: A Deciding Factor for Success
  • The Biosimilar Movement
  • Regional Market Overview
    • Table 9-3: Precision Cancer Therapeutics Market Summary by Geographical Region, 2022-2027 ($ millions)
  • United States and Canada
    • Table 9-4: Precision Cancer Therapeutics Market Summary for U.S. and Canada, 2022-2027 ($ millions)
    • Figure 9-2: Precision Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 %
  • EMEA
    • Table 9-5: Precision Cancer Therapeutics Market Summary for EMEA, 2022-2027 ($ millions)
    • Figure 9-3: Precision Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
  • Asia Pacific
    • Table 9-6: Precision Cancer Therapeutics Market Summary for Asia Pacific, 2022-2027 ($ millions)
    • Figure 9-4: Precision Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
  • Latin America
    • Table 9-7: Precision Cancer Therapeutics Market Summary for Latin America, 2022-2027 ($ millions)
    • Figure 9-5: Precision Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)

Chapter 10: Market Participants

  • Top 15 Overview
    • Table 10-1: Global Market Participants for Precision Cancer Therapeutics, Top 15 Companies, 2022 ($ in millions)
    • Figure 10-1: Global Market Share for Precision Cancer Therapeutics, 2022 %
    • Figure 10-2: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ in millions)
    • Figure 10-3: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics
  • AbbVie, Inc.
    • Table 10-2: AbbVie Corporate Summary
  • Company Summary
  • Amgen
    • Table 10-3: Amgen Corporate Summary
  • Company Summary
  • Astellas Pharma U.S., Inc
    • Table 10-4: Astellas Corporate Summary
  • Company Summary
  • AstraZeneca PLC
    • Table 10-5: AstraZeneca Corporate Summary
  • Company Summary
  • Bayer AG
    • Table 10-6: Bayer Corporate Summary
  • Company Summary
  • Bristol-Myers Squibb Company
    • Table 10-7: Bristol-Myers Squibb Corporate Summary
  • Company Summary
  • Clovis Oncology, Inc.
    • Table 10-8: Clovis Oncology Corporate Summary
  • Company Summary
  • Dendreon Pharmaceuticals LLC
    • Table 10-9: Dendreon Corporate Summary
  • Company Summary
  • Eli Lilly & Company
    • Table 10-10: Eli Lilly Corporate Summary
  • Company Summary
  • EMD Serono, Inc. (Merck KgaA)
    • Table 10-11: EMD Serono Corporate Summary
  • Company Summary
  • Eisai Co., Ltd.
    • Table 10-12: Eisai Corporate Summary
  • Company Summary
  • Exelixis, Inc.
    • Table 10-13: Exelixis Corporate Summary
  • Company Summary
  • Gilead Sciences, Inc.
    • Table 10-14: Gilead Sciences Corporate Summary
  • Company Summary
  • GlaxoSmithKline
    • Table 10-15: GSK Corporate Summary
  • Company Summary
  • Johnson & Johnson
    • Table 10-16: Johnson & Johnson Corporate Summary
  • Company Summary
  • Merck & Co., Inc.
    • Table 10-17: Merck & Co. Corporate Summary
  • Company Summary
  • Novartis AG
    • Table 10-18: Novartis Corporate Summary
  • Company Summary
  • Otsuka Holdings Co., Ltd.
    • Table 10-19: Otsuka Corporate Summary
  • Company Summary
  • Pfizer, Inc.
    • Table 10-20: Pfizer Corporate Summary
  • Company Summary
  • Puma Biotechnology, Inc.
    • Table 10-21: Puma Biotechnology Corporate Summary
  • Company Summary
  • Roche (F. Hoffman-La Roche, Ltd.)
    • Table 10-22: Roche Corporate Summary
  • Company Summary
  • Sanofi/Genzyme
    • Table 10-23: Sanofi/Genzyme Corporate Summary
  • Company Summary
  • Seagen Inc.
    • Table 10-24: Seagen Corporate Summary
  • Company Summary
  • Takeda Oncology - Millennium Pharmaceuticals
    • Table 10-25: Takeda Oncology Corporate Summary
  • Company Summary
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!